Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Optical quality after Nd:YAG laser capsulotomy assessed with a double-pass technique

Poster Details

First Author: B.Ortíz de Zárate SPAIN

Co Author(s):    A. Gonzalez   E. Lopez                 

Abstract Details

Purpose:

Posterior capsule opacification (PCO) is the most common postoperative complication among pseudophakic patients, and it leads to a reversible loss of visual acuity. In multifocal lens wearers, slight opacifications can cause a larger visual impact, as measured subjectively.

Setting:

IOA Madrid Innova Ocular, Madrid, Spain

Methods:

Forty-six eyes from 34 patients (20 females and 14 males) were analysed in this interventional study. Mean age was 67 years (range: 44 to 86). Both monofocal and multifocal lens wearers were included. To measure visual quality a double-pass system was employed (Optical quality analysis system). More specifically, the metrics under study were The Objective Scatter Index (OSI) and the Modulation Transfer Function (MTF). A thorough examination, which included Visual acuity (VA), intra-ocular pressure (IOP) and biomicroscopy, MTF and OSI measurements, was performed both pre-and post-Nd:YAG-laser capsulotomy. Mean time from surgery to capsulotomy was 64 months (range: 6 to 81).

Results:

For multifocal lens wearers, the MTF was 13,14 (pre-capsulotomy) vs. 23.31 (post-capsulotomy) and the OSI was 4,98 (pre-capsulotomy) vs. 2,18 (post-capsulotomy). As for monofocal lens wearers, the MTF went from 14,22 (pre-capsulotomy) to 29.65 (post-capsulotomy) and the OSI went from 3,76 (pre-capsulotomy) to 1,34 (post-capsulotomy).

Conclusions:

Being able to objectively measure MTF and OSI is of invaluable help when it comes to deciding to either perform a capsulotomy, or replace the multifocal intraocular lenses altogether, if the patient has intolerance to them.

Financial Disclosure:

NONE

Back to Poster listing